
Opinion|Videos|December 9, 2024
Disability Accumulation and Early Therapy: Insights from MAGNIFY-MS and High-Efficacy DMT Data
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Cladribine reduces disability accumulation in both treatment-naive and previously treated patients, highlighting the importance of early therapy initiation.
- High-efficacy DMTs, including ocrelizumab, ofatumumab, and S1P receptor modulators, effectively manage PIRA and mitigate disability progression.
Panelists discuss how the MAGNIFY-MS study underscores the significance of early, aggressive multiple sclerosis (MS) treatment with cladribine, demonstrating its potential to effectively mitigate disability progression through progression independent of relapse activity (PIRA) suppression in both treatment-naive and previously treated patient populations, with outcomes competitive with other high-efficacy disease-modifying therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Stefano et al presented data on disability accumulation (PIRA, relapse-associated worsening, confirmed disability accumulation) with cladribine from the MAGNIFY-MS study that show the importance of early initiation of therapy. Please highlight disability accumulation in both treatment-naive and previously treated groups.
- Please share an overview of PIRA data with other high-efficacy disease-modifying therapies (DMTs) (ocrelizumab, ofatumumab, S1P receptor modulators, etc).
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026
2
Clinical Perspectives on Promising Phase 1 Data of CAPN2-Targeting Therapy AMX0114 for ALS
3
Previewing Expected FDA Decisions in Neurology for 2026
4
NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care?
5





























